Sugi Predict

Sugi Predict / Compounds / SCHEMBL4182528

SCHEMBL4182528

SCHEMBL4182528

O=C(O)CCCCc1nnc(-c2ccccc2O)o1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.54
▸ HPGD P15428 2/20 0.54
▸ HSD17B10 Q99714 2/20 0.54
▸ PKM P14618 1/20 0.54
▸ TSHR P16473 1/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ RXRA P19793 2/20 0.47
▸ RXRB P28702 2/20 0.47
▸ NR4A2 P43354 2/20 0.47
▸ HDAC3 O15379 1/20 0.46
▸ HDAC4 P56524 1/20 0.46
▸ HDAC1 Q13547 1/20 0.46
▸ HDAC7 Q8WUI4 1/20 0.46
▸ HDAC2 Q92769 1/20 0.46
▸ HDAC10 Q969S8 1/20 0.46
▸ HDAC11 Q96DB2 1/20 0.46
▸ HDAC8 Q9BY41 1/20 0.46
▸ HDAC6 Q9UBN7 1/20 0.46
▸ HDAC9 Q9UKV0 1/20 0.46
▸ HDAC5 Q9UQL6 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10102734 0.82 HDAC8 (0.65) KDM4EHPGDPKMTSHRRXRA
SCHEMBL3043539 0.77 HDAC1 (0.54) RXRARXRBNR4A2HDAC3HDAC4
SCHEMBL1809729 0.77 FAAH (0.60) KDM4EHPGDPKMHDAC3HDAC4
SCHEMBL13478063 0.77 FAAH (0.60) RXRARXRBNR4A2HDAC3HDAC4
SCHEMBL13698879 0.76 FAAH (0.62) KDM4EHPGDHDAC3HDAC4HDAC1
SCHEMBL3049395 0.75 RXRA (0.56) KDM4EHPGDTSHRMAPK1RXRA
SCHEMBL3046300 0.75 RXRA (0.46) HPGDMAPK1RXRARXRBNR4A2
SCHEMBL3045765 0.75 CHUK (0.59) KDM4EHPGDHSD17B10MAPK1RXRA
SCHEMBL3041340 0.75 RXRA (0.43) MAPK1RXRARXRBNR4A2HDAC3
SCHEMBL3043550 0.74 RXRA (0.45) HPGDMAPK1RXRARXRBNR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4259799-A1 ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 Civi Biopharma, Inc. (US) 2023-10-18 — — EP claimed
CN-116897206-A Oral delivery of PCSK 9-targeting antisense conjugates 四纬生物制药股份有限公司 2023-10-17 — — CN claimed
WO-2022125913-A9 ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 CIVI BIOPHARMA, INC. (US) 2023-06-08 — — WO claimed
WO-2022125913-A1 ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 CIVI BIOPHARMA, INC. (US) 2022-06-16 — — WO claimed
EP-4326329-A1 ORAL DELIVERY OF OLIGONUCLEOTIDES Civi Biopharma, Inc. (US) 2024-02-28 — — EP disclosed
CN-117545509-A Oral delivery of oligonucleotides 四纬生物制药股份有限公司 2024-02-09 — — CN disclosed
EP-4259799-A1 ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 Civi Biopharma, Inc. (US) 2023-10-18 — — EP disclosed
CN-116897206-A Oral delivery of PCSK 9-targeting antisense conjugates 四纬生物制药股份有限公司 2023-10-17 — — CN disclosed
WO-2022125913-A9 ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 CIVI BIOPHARMA, INC. (US) 2023-06-08 — — WO disclosed
WO-2022125913-A1 ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 CIVI BIOPHARMA, INC. (US) 2022-06-16 — — WO disclosed
EP-2409569-B1 Method for administering GLP-1 molecules EMISPHERE TECH INC (US) 2017-08-16 — — EP disclosed
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) 2017-07-06 — — US disclosed
US-20110178006-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES EMISPHERE TECHNOLOGIES, INC. (US) 2011-07-21 — — US disclosed
US-20110178006-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES EMISPHERE TECHNOLOGIES, INC. (US) 2011-07-21 — — US disclosed
US-7939494-B2 Method for administering GLP-1 molecules EMISPHERE TECHNOLOGIES, INC. (US) 2011-05-10 — — US disclosed
US-7939494-B2 Method for administering GLP-1 molecules EMISPHERE TECHNOLOGIES, INC. (US) 2011-05-10 — — US disclosed
US-20090286735-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) 2009-11-19 — — US disclosed
US-20090286735-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) 2009-11-19 — — US disclosed
WO-2009100245-A1 LOW DOSE HMG-COA REDUCTASE INHIBITOR WITH REDUCED SIDE EFFECTS EMISPHERE TECHNOLOGIES INC. (US) 2009-08-13 — — WO disclosed
WO-2009100245-A1 LOW DOSE HMG-COA REDUCTASE INHIBITOR WITH REDUCED SIDE EFFECTS EMISPHERE TECHNOLOGIES INC. (US) 2009-08-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178006-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES GLP1R, GIPR, GPR119 KDM4E 4046/4885HPGD 2135/4885HSD17B10 2528/4885
US-20090286735-A1 METHOD FOR ADMINISTERING GLP-1 MOLECULES GLP1R, GIPR, GPR119 KDM4E 4046/4885HPGD 2135/4885HSD17B10 2528/4885
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS SI, SLC20A1, SLC20A2 KDM4E 4162/4885HPGD 1489/4885HSD17B10 1827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.